ArticleImmunity & ageing : I & A2017
pERK-dependent defective TCR-mediated activation of CD4
Article in Immunity & ageing : I & A, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Cutaneous adaptive immunity and uraemia: a narrative review.Frontiers in immunology · 2024Review
- Older age is associated with a distinct and marked reduction of functionality of both alloreactive CD4+ and CD8+ T cells.Frontiers in immunology · 2024Article
- Lowering maintenance immune suppression in elderly kidney transplant recipients; connecting the immunological and clinical dots.Frontiers in medicine · 2023Review
- Aberrant signaling of immune cells in Sjögren's syndrome patient subgroups upon interferon stimulation.Frontiers in immunology · 2022Article
- Uremia-Associated Immunological Aging and Severity of COVID-19 Infection.Frontiers in medicine · 2021Review
- DUSP6 protects murine podocytes from high glucose‑induced inflammation and apoptosis.Molecular medicine reports · 2020Article
- Premature aging of circulating T cells predicts all-cause mortality in hemodialysis patients.BMC nephrology · 2020Article
- Review
- T-cell aging in end-stage renal disease: an evolving story with CMV.Medical microbiology and immunology · 2019Review
- Human Epididymis Secretory Protein 4 (HE4) Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6.Frontiers in pharmacology · 2019Article
- A comprehensive characterization of aggravated aging-related changes in T lymphocytes and monocytes in end-stage renal disease: the iESRD study.Immunity & ageing : I & A · 2018Article
- End-Stage Renal Disease Causes Skewing in the TCR Vβ-Repertoire Primarily within CD8Frontiers in immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with end-stage renal disease (ESRD) have an impaired immune response with a prematurely aged T-cell system. Mitogen-activated protein kinases (MAPKs) including extracellular signal-regulated kinase (ERK) and p38, regulate diverse cellular programs by transferring extracellular signals into an intracellular response. T cell receptor (TCR)-induced phosphorylation of ERK (pERK) may show an age-associated decline, which can be reversed by inhibiting dual specific phosphatase (DUSP) 6, a cytoplasmic phosphatase with substrate specificity to dephosphorylate pERK. The aim of this study was to assess whether ESRD affects TCR-mediated signaling and explore possibilities for intervening in ESRD-associated defective T-cell mediated immunity.
resultsAn age-associated decline in TCR-induced pERK-levels was observed in the different CD4
conclusionsTCR-mediated phosphorylation of ERK is affected in young ESRD patients consistent with the concept of premature immunological T cell ageing. Inhibition of DUSP6 specific for pERK might be a potential intervention enhancing T-cell mediated immunity in ESRD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.